Summary Background In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended in the USA for prevention of invasive pneumococcal disease in …
Centers for Disease Control and … - MMWR. Morbidity …, 2010 - pubmed.ncbi.nlm.nih.gov
On February 24, 2010, a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.]) was licensed by the Food and Drug …
Centers for Disease Control and … - MMWR. Morbidity …, 2010 - pubmed.ncbi.nlm.nih.gov
Invasive pneumococcal disease (IPD), caused by Streptococcus pneumoniae (pneumococcus), remains a leading cause of serious illness in children and adults …
HL Platt, D Greenberg, B Tapiero… - The Pediatric …, 2020 - journals.lww.com
Background: Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and …
S Senders, NP Klein, E Lamberth… - The Pediatric …, 2021 - journals.lww.com
Background: The development and widespread use of pneumococcal conjugate vaccines (PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the …
Importance Immunization schedules with pneumococcal conjugate vaccine (PCV) differ among countries regarding the number of doses, age at vaccinations, and interval between …
SP Fitzwater, A Chandran, M Santosham… - The Pediatric …, 2012 - journals.lww.com
Background: Pneumococcal conjugate vaccines (PCV) are emerging as one of the most promising means to prevent pediatric disease. The 7-valent PCV (PCV-7) has been …